Literature DB >> 29200101

Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma.

Justin M M Cates1.   

Abstract

Extent of response to neoadjuvant chemotherapy, tumor size, and patient age are important prognostic variables for patients with osteosarcoma, but applying information from these continuous variables in survival models is difficult. Dichotomization is usually inappropriate and alternative statistical techniques should be considered instead. Nonlinear multivariable regression methods (restricted cubic splines and fractional polynomials) were applied to data from the National Cancer Database to model continuous prognostic factors for overall survival from localized, high-grade osteosarcoma of the appendicular and nonspinal skeleton following neoadjuvant chemotherapy and surgical resection (N=2493). The assumption that log hazard ratios were linear in relation to these continuous prognostic factors was tested using likelihood ratio tests of model deviance and Wald tests of spline coefficients. Log hazard ratios for increasing patient age were linear over the range of 4 to 80 years, but showed evidence for variation in the coefficient over elapsed follow-up time. Tumor size also showed a linear relationship with log hazard over the range of 1 to 30 cm. Hazard ratios for chemotherapy effect profoundly deviated from log-linear (P<0.004), with significantly decreased hazard for death from baseline for patients with ≥90% tumor necrosis (hazard ratio, 0.32; 95% confidence interval, 0.20-0.52; P<0.0001). Important implications of these results include: (1) ≥90% tumor necrosis defines good chemotherapy response in a clinically useful manner; (2) staging osteosarcoma by dichotomizing tumor size is inappropriate; and (3) patient age can be modeled as a linear effect on the log hazard ratio in prognostic models with the caveat that risk may change over duration of the analysis.

Entities:  

Mesh:

Year:  2018        PMID: 29200101     DOI: 10.1097/PAS.0000000000000995

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last?

Authors:  Zining Liu; Yinkui Wang; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Ziyu Li; Jiafu Ji
Journal:  Cancer Manag Res       Date:  2021-01-11       Impact factor: 3.989

Review 2.  Future Directions in the Treatment of Osteosarcoma.

Authors:  Alannah Smrke; Peter M Anderson; Ashish Gulia; Spyridon Gennatas; Paul H Huang; Robin L Jones
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

3.  Analysis of Clinical Manifestations and Prognostic Factors Affecting Osteosarcoma.

Authors:  Jianghua Wei; Zhizhong Liang; Gang Xu
Journal:  Dis Markers       Date:  2022-08-04       Impact factor: 3.464

4.  Long noncoding RNA taurine-up regulated gene 1 for the prognosis of osteosarcoma: A protocol for meta-analysis and bioinformatics analysis.

Authors:  Zheng Ren; Chenyang Li; Yuling Gan; Xiuxin Liu; Fudong Liang
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

5.  Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice.

Authors:  Sun Xin; Guo Wei
Journal:  J Bone Oncol       Date:  2020-02-21       Impact factor: 4.072

6.  A Prognostic Model to Assess Long-Term Survival of Patients on Antiretroviral Therapy: A 15-Year Retrospective Cohort Study in Southwestern China.

Authors:  He Jiang; Qiuying Zhu; Yi Feng; Jinghua Huang; Zongxiang Yuan; Xinjuan Zhou; Guanghua Lan; Hao Liang; Yiming Shao
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.